| HS Code | 722471 |
| Product Name | Yuejiaoxian® Recombinant Fibronectin (XL01) |
| Catalog Number | XL01 |
| Source | Recombinant Human Fibronectin |
| Expression System | HEK293 cells |
| Purity | ≥95% (SDS-PAGE) |
| Formulation | Lyophilized powder |
| Molecular Weight | Approx. 220 kDa |
| Storage Temperature | -20°C or lower |
| Application | Cell culture coating |
| Sterility | Sterile filtered |
| Endotoxin Level | <1.0 EU/µg |
| Solubility | Soluble in sterile water or PBS |
| Species | Human |
| Batch Testing | Tested for cell adhesion activity |
As an accredited Yuejiaoxian® Recombinant Fibronectin (XL01) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | The `Yuejiaoxian® Recombinant Fibronectin (XL01)` is packaged in a sterile 1 mg vial, sealed in a labeled protective box. |
| Shipping | **Shipping Description:** Yuejiaoxian® Recombinant Fibronectin (XL01) is shipped on dry ice to ensure product stability and preserve bioactivity during transit. The package is securely insulated, maintaining the required low temperatures for the duration of shipping. Upon arrival, promptly store at -80°C, avoiding repeated freeze-thaw cycles. |
| Storage | Yuejiaoxian® Recombinant Fibronectin (XL01) should be stored at -20°C in a dry, tightly sealed container to maintain stability and prevent degradation. Avoid repeated freeze-thaw cycles to preserve protein activity. Upon thawing, store the product at 2–8°C and use within one week. Protect from light and contamination. Follow manufacturer’s guidelines for optimal storage and handling practices. |
As the original manufacturer of Yuejiaoxian® Recombinant Fibronectin (XL01), we supply this advanced biomaterial for specialized downstream industrial applications. The following sectors directly apply XL01 for high-performance formulations, supported by strict compliance, technical integration points, and reliable commercial usage benchmarks.
Biopharmaceutical manufacturers incorporate this recombinant fibronectin as an essential extracellular matrix protein within advanced cell culture systems, especially in large-scale manufacturing of monoclonal antibodies or recombinant proteins. Cell attachment, spreading, and proliferation depend on the reproducible quality of cell culture surfaces, which directly impacts batch consistency and final product purity. Only GMP-certified, animal-origin-free fibronectin meets the stringent safety and traceability requirements for regulated bioreactor operations. Customers select XL01 based on its high purity, consistent molecular structure, and excellent binding capacity.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Animal component-free cell culture and regenerative medicine applications require chemically defined media, with recombinant fibronectin replacing animal-derived matrix proteins. Downstream users formulate XL01 to support stem cell expansion, primary cell maintenance, and differentiation protocols, achieving batch-to-batch consistency while eliminating risks of viral or prion contamination. This protein's high biological activity and lot-specific characterization make it suitable for complex media blends used in vaccine and advanced therapy manufacturing.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Manufacturers of implantable and diagnostic medical devices utilize recombinant fibronectin as a bioactive coating to enhance surface biocompatibility and promote in vivo cell adhesion. This approach applies especially to biosensors, tissue scaffolds, and prosthetic interfaces where cellular integration is critical for device acceptance and function. Production environments demand validated raw material traceability and surface modification protocols, relying on the recombinant, animal-origin-free composition of XL01 to minimize immunogenicity risks and meet health authority certifications.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Producers of hydrogel and polymer scaffolds for 3D cell culture or tissue engineering applications incorporate recombinant fibronectin as a critical matrix component to facilitate cell attachment and promote multilineage differentiation. The raw material supports advanced scaffold architectures, enabling uniform cell distribution and functional tissue formation. Downstream workflows require documented protein purity and bioactivity, with integration into aqueous or cross-linked gel systems, ensuring compatibility with clinical or preclinical testing demands.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Cell and gene therapy manufacturers rely on high-purity, xeno-free recombinant fibronectin to support ex vivo expansion, differentiation, and formulation of therapeutic cell products for transplantation or in vivo delivery. Process chemists monitor every ancillary input for consistency and compliance, and regulatory submissions demand detailed traceability for all biological raw materials. XL01's batch homogeneity, GMP documentation, and viral clearance validation underpin its acceptance for use in therapy processes moving through clinical and commercial phases.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive Yuejiaoxian® Recombinant Fibronectin (XL01) prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Day-to-day in our lab, we keep a sharp focus on the needs of scientists who drive cellular studies and biomedical advances. Recombinant fibronectin easily stands out as an anchor in this area. The move away from animal-derived products has become more than a trend—safety, lot-to-lot consistency, and the demand for better-defined components push researchers and manufacturers to invest in recombinant solutions.
We developed Yuejiaoxian® Recombinant Fibronectin (XL01) with a clear target: to support those looking for high-purity, animal-free substrates for cell culture and regenerative medicine. Drawing from our years of upstream processing and downstream purification experience, we tailored this product to help users avoid the batch variations, viral contaminants, and ethical concerns that often arise with plasma-sourced alternatives. Each lot comes out meeting the same traceability and functional benchmarks that major labs rely on every day.
Quality stands at the center of every production run in our facility. XL01 comes as a full-length recombinant protein, produced in a tightly controlled, animal component-free expression system. We do not compromise on source material at any stage. Our team handles everything from seed banking and fermentation to purification and bottling in our own GMP-grade workshops. Hands-on oversight from process scientists means the identity and structure of XL01 remain consistent, without irregular fragments or contaminants. Each batch undergoes stringent identity, purity, and biological activity checks—those checks have been refined through direct feedback with cell therapy development groups. Our approach gives you results that line up batch after batch, so your workflow doesn’t run into unexpected surprises.
We ship each lot with a final purity routinely exceeding 95%, confirmed by SDS-PAGE and mass spectrometry. Levels of endotoxin, host cell proteins, and DNA are controlled to meet the demands of sensitive primary cell or stem cell environments. We see many of our users coating cultureware for iPSC maintenance, mesenchymal or neural cell expansion, and differentiation assays. Consistent biological activity supports attachment and spreading across a range of cell lines, including those difficult to culture using other matrices.
We see plenty of cell culture substrates in today’s market, but few stand up to close technical scrutiny when it comes to recombinant fibronectin. We manufacture XL01 entirely from recombinant sources, with no ties to plasma pools or animal extracts. Other manufacturers may claim recombinant production, but we have observed through direct customer analysis that inconsistent filtration or low-purity bulk supply often leave behind either fragments or protein byproducts.
Our team tracks every step—from the formulation buffer to filling—to make sure the integrity of the fibronectin remains intact. Solubility tests and shelf-life trials guide our storage recommendations, but we also invite end users to reach out for stability data under their preferred handling workflows. We share full analytical profiles, including spectrophotometric and chromatographic characterizations, so research teams can match our data to their needs.
During collaborations with stem cell technology companies, we ran side-by-side adhesion and proliferation comparisons between XL01 and popular animal-derived fibronectins. XL01 supported equivalent or better attachment for human embryonic stem cells and induced pluripotent stem cells, even at lower coating concentrations. Reported reproducibility in colony size and morphology confirmed results seen in our own internal testing. Labs that previously struggled with spontaneous differentiation events reported fewer interruptions after switching to XL01.
Groups working on clinical workflows and regenerative therapies increasingly avoid animal and human blood-derived products, both for regulatory reasons and quality insurance. Traditional fibronectin comes from plasma pools, introducing risks of unknown bioburden, viruses, or even immunogenic fragments that can complicate downstream assays. For teams with a focus on translational work and those seeking to minimize all variables in their cultures, switching to recombinant platforms represents a major step forward.
We welcome discussions about our sourcing, production traceability, and residual impurity levels. Recent collaborations with tissue engineering teams highlighted the importance of predictable surface chemistry on engineered scaffolds—XL01’s lot-to-lot reproducibility gave these teams freedom to focus on process development without concerns about micro-environment inconsistencies. For applications like organoid growth or high-throughput screening, where even small culture changes can disrupt whole experiments, access to a reliable, animal-free recombinant fibronectin pays off.
Most researchers in our network use XL01 as a coating substrate for cell culture plates, flasks, or microcarriers. Surface adsorption saturates quickly; micrograms per square centimeter suffice for many lines. For high-throughput screen development, adding XL01 to media supports early stage attachment in suspension systems. Cell therapy teams use our product both to expand primary cells and to drive differentiation. The flexibility in concentration allows teams to fine-tune their own protocols rather than work around constraints imposed by impure or unstable animal-derived alternatives. We designed XL01 to dissolve rapidly and withstand multiple freeze-thaw cycles, factors we know simplify day-to-day operations.
Several teams have also adopted XL01 for use with 3D scaffolds, thanks to its predictable bioactivity and consistent chemistry. Research groups working with synthetic biomaterials find that recombinant fibronectin improves cell adherence on polymers and hydrogels, supporting applications from tissue models to cell encapsulation. Our collaborations with microfluidic developers underscore the benefit of a defined coating when fluid shear and confined growth push cells to their limits—using recombinant fibronectin brings better reproducibility and reliability in these emerging formats.
As direct producers, we see our support work does not stop at shipping out a finished vial. Feedback from end users reveals subtle differences in surface coating efficiency, stability in diverse storage conditions, and compatibility with other defined media. We prioritize transparent communication. We welcome those working under strict documentation or certification demands to explore our audit trail, raw material traceability, and handling SOPs. Our technical team assists labs in optimizing coating protocols or troubleshooting issues that arise with difficult cell lines, passing on the experience we have built through hours spent piloting our own stem cell and primary culture workflows.
Ongoing dialogue with academic labs, biotech start-ups, and large therapeutic manufacturing teams drives our improvements. Whether a team faces an out-of-spec adherence curve, wants analytical verification of protein identity, or needs to align material handling to ISO or cGMP standards, we provide rapid, informed responses backed by direct production expertise. Several groups have credited our approach for rescue of previously abandoned protocols, all due to our willingness to match product support with the same rigor seen in our production labs.
We have noticed that researchers and production teams working toward IND filings or clinical-grade cell therapy face more questions about their substrates than ever. XL01 production takes place under cleanroom conditions with controlled raw materials and full batch documentation. We provide certificates of analysis, and on request, we share virus safety data, full genetic construct characterization, and impurity profiles down to part-per-billion where needed. This targeted transparency allows regulatory officers and quality managers to quickly assess risk and consider XL01 as an animal-free, xenogeneic-free matrix, bypassing lengthy origin disclosure stages.
Facility audits from both public and private sector clients have helped us strengthen our internal protocols, leading to practical improvements in operator training, raw material validation, and traceable sample archiving. Across all documentation, we commit to scientific accuracy, without exaggerating claims or obscuring specifications. Our own GMP training programs and regular batch review meetings keep this focus sharpened, and have passed scrutiny from both local regulators and international clients seeking documentation suitable for export filings.
Research does not always conform to fixed concentrations or preset configuration needs. We package XL01 at working concentrations from hundreds of micrograms up to multigram lots, tailored for everything from pilot experiments to preclinical manufacturing. We support requests for bulk packaging, custom buffers, or minor formulation adjustments—every production run takes place in our facility. Teams working with automated liquid handlers or bioreactors appreciate our ability to fill large volumes without reformatting, while small academic labs benefit from aliquots that can be accessed multiple times without waste.
If a group requires a validated fill-finish process with extra controls, we match our documentation to their needs. Several times, we have worked hand-in-hand with process teams developing customized protocols that integrate into automated workflows or multi-user platforms, making sure quality and usability remain at the forefront.
Fibronectin’s role as an attachment protein extends beyond traditional cell expansion. Its interaction with integrins affects differentiation, pluripotency, and even cell fate decisions in many systems. Using recombinant, animal-free fibronectin gives research teams an essential tool for removing outside variables from their experiments. Stem cell engineers, tissue modelers, and regenerative medicine specialists all report confidence in knowing exactly what is in their system. In recent years, as more work moves toward clinical translation, labs tell us that having a defined, documented, and transparent cell substrate streamlines regulatory filing and supplier audit steps.
We see regular discussion around price, yield, and security of supply for defined biomaterial inputs. By managing our own production and supply chain, we commit to safeguarding access for teams ranging from university spinouts up to industrial biomanufacturers seeking robust alternate sourcing. Our facility has managed multiple scale-ups in response to high-volume customer requests, all while keeping release standards on par with lab-scale output.
Our leadership team includes process engineers, research scientists, and field application specialists who apply lessons from every user interaction into each subsequent production cycle. Whether we refine our purification workflow or upgrade our analytics, the goal remains clear: deliver a product that both we and our users can rely on. We do not treat feedback as a marketing checkbox—instead, we use concrete user cases to push for better yield, improved filtration, or even easier handling for bench scientists.
In the growing field of regenerative medicine, scaling from benchtop to clinic creates new technical and regulatory pressures every year. XL01 stands as an example of our work to bridge the lab-manufacturer gap. From original cell line authentication to final fill-finish protocols, we shape every step with input from our downstream partners.
Industry-wide, the progress in animal-free biomaterials continues to speed up. Demands from emerging cell and gene therapies push for even tighter documentation, more reliable risk mitigation, and predictable long-term supply. Our experience manufacturing XL01 has convinced us that authentic, traceable recombinant products offer both immediate value and future-proofing. Every direct feedback cycle—whether as a technical troubleshooting session or regulatory audit—shows that moving away from animal-based inputs pays off at every level. We remain hands-on, dialog-driven producers, supporting the research community with transparency, technical rigor, and practical solutions.
Yuejiaoxian® Recombinant Fibronectin (XL01) represents our ongoing response to the shifting landscape of defined substrate manufacturing. We welcome every inquiry, every request for data, and every technical challenge that brings us closer to building reliable, innovative, and accessible scientific tools. Our product does not aim to be one-size-fits-all; it reflects a commitment to clear manufacturing, open dialogue, and true partnership with the science community.
